Prostate cancer (PCa) is the most common solid-organ cancer in American males and the second most common cause of cancer-related death in men.With the advent of prostate-specific antigen screening,death from PCa continues to decline.However,recent evidence suggests that there is now a trend towards increasing incidence.1 Current screening strategies result in increased incidence of low-risk PCa and importantly,the diagnosis of PCa is becoming more common in younger patients.2 The majority of early-stage PCa patients have a high likelihood of disease free survival after treatment.Localized disease is most commonly treated with radical prostatectomy,external beam radiation therapy (EBRT)or brachytherapy.Local therapy yields excellent long-term survival results in low-risk patients;however,treatments may result in a significant treatment-related morbidity,and ultimately impact patient health-related quality of life (HRQOL).3 The effects of these treatment modalities on the HRQOL have been evaluated and compared and all three are associated with increased sexual dysfunction.